Babies born to HIV-positive mothers and given the antiretroviral drug nevirapine through the first six weeks of life to prevent infection via breast-feeding are at high risk for developing drug-resistant HIV if they get infected anyway, a team of researchers report. But the investigators highlight the proven superiority of the six-week regimen in preventing mother-to-child
Full Post: Prolonged nevirapine in breast-fed babies prevents HIV infection but leads to drug-resistant HIV
A new study from Barts and The London School of Medicine and Dentistry has found that a common treatment for wheezing in preschool children is no more effective than a placebo.
The findings, reported in the January edition of The New England Journal of Medicine, call into question national guidelines for the treatment of viral-induced wheezing.
Attacks of wheezing caused by viral infections in the upper respiratory tract are common in preschool children between the ages of ten months and six years. Preschool children who visit hospital with such symptoms are commonly treated with a short course of prednisolone - a steroid which is used to reduce inflammation in the airway and which is very effective in treating attacks of allergic asthma in older children and adults.
It has recently been recognised that wheeze in most preschool children is only triggered by viral colds, and is therefore a different condition from ‘allergic asthma’. There is conflicting evidence whether a short course of oral prednisone is effective in this age group.
Professor Jonathan Grigg, a paediatrician at Barts and The London’s, Institute of Cell and Molecular Science, along with colleagues from Leicester and Nottingham Universities, studied a group of 700 children between the ages of 10 and 60 months, who presented to hospital with an attack of wheezing associated with a viral infection. Half were treated with oral prednisolone, half with a placebo, and symptoms monitored by health care professionals.
The team found no significant difference in the length of time the children spent in hospital between the placebo group and the prednisolone group. These findings were consistent with a previous study conducted by the team, where the oral steroid was administered by parents in the home.
Professor Grigg explains: “The result of this large trial suggests that oral prednisolone should not be routinely given to preschool children presenting to the hospital with virus-induced wheezing.”
http://www.qmul.ac.uk/
--------------------------------------------------------------------------------------------
Related Posts:
Up to 150,000 people suffering from severe asthma in the UK could benefit from taking antifungal medication already available from pharmacists, new research has found. University of Manchester scientists found that pills used to treat everyday fungal infections greatly improved symptoms of asthma in those patients that had an allergic reaction to one or more
Full Post: Antifungal medication could provide asthma relief for 150,000 UK sufferers
Data presented today at the American College of Allergy, Asthma & Immunology (ACAAI) show that Xolair (Omalizumab) for Subcutaneous Use significantly reduced asthma attacks in children aged six through 11 with moderate or severe persistent allergic asthma inadequately controlled with inhaled corticosteroids. The study further defines the safety profile of Xolair in this patient population.
Full Post: Xolair (Omalizumab) shows promise in treating allergic asthma inadequately controlled by inhaled corticosteroid
Tufts researchers and colleagues report that place of birth plays a role in the occurrence of asthma in a United States black population. The researchers found that within one inner-city population, blacks born in the United States were more likely to have asthma than blacks who were born outside of the United States. “Within Asian
Full Post: Place of birth plays a role in the occurrence of asthma in U.S black population
The National Association of County and City Health Officials (NACCHO) has announced a donation of up to one million doses of FluMist (Influenza Virus Vaccine Live, Intranasal) by MedImmune in a partnership aimed at increasing influenza awareness and vaccinations in underserved communities and populations. NACCHO will make these donated doses of vaccine available to selected state
Full Post: NACCHO to donate up to one million doses of FluMist
The following is GlaxoSmithKline’s statement regarding recommendations of a combined Advisory Committee to the FDA on the use of asthma medicines containing long-acting beta agonists, including GSK’s Serevent (salmeterol) and Advair (salmeterol/fluticasone proprionate). “We welcome the committee’s endorsement of Advair as a safe and effective treatment for asthma in adults and children,” said Dr. Ellen
Full Post: GlaxoSmithKline statement on FDA advisory committee vote on use of asthma medicines containing long-acting beta agonists --------------------------------------------------------------------------------------------
